Anti-LCN8/ EP17/ LCN5 functional antibody

Anti-LCN8/ EP17/ LCN5 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to LCN8/LCN8 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE1063-Ab-1/ GM-Tg-hg-SE1063-Ab-2Anti-Human LCN8 monoclonal antibodyHuman
GM-Tg-rg-SE1063-Ab-1/ GM-Tg-rg-SE1063-Ab-2Anti-Rat LCN8 monoclonal antibodyRat
GM-Tg-mg-SE1063-Ab-1/ GM-Tg-mg-SE1063-Ab-2Anti-Mouse LCN8 monoclonal antibodyMouse
GM-Tg-cynog-SE1063-Ab-1/ GM-Tg-cynog-SE1063-Ab-2Anti-Cynomolgus/ Rhesus macaque LCN8 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE1063-Ab-1/ GM-Tg-felg-SE1063-Ab-2Anti-Feline LCN8 monoclonal antibodyFeline
GM-Tg-cang-SE1063-Ab-1/ GM-Tg-cang-SE1063-Ab-2Anti-Canine LCN8 monoclonal antibodyCanine
GM-Tg-bovg-SE1063-Ab-1/ GM-Tg-bovg-SE1063-Ab-2Anti-Bovine LCN8 monoclonal antibodyBovine
GM-Tg-equg-SE1063-Ab-1/ GM-Tg-equg-SE1063-Ab-2Anti-Equine LCN8 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE1063-Ab-1/ GM-Tg-hg-SE1063-Ab-2; GM-Tg-rg-SE1063-Ab-1/ GM-Tg-rg-SE1063-Ab-2;
GM-Tg-mg-SE1063-Ab-1/ GM-Tg-mg-SE1063-Ab-2; GM-Tg-cynog-SE1063-Ab-1/ GM-Tg-cynog-SE1063-Ab-2;
GM-Tg-felg-SE1063-Ab-1/ GM-Tg-felg-SE1063-Ab-2; GM-Tg-cang-SE1063-Ab-1/ GM-Tg-cang-SE1063-Ab-2;
GM-Tg-bovg-SE1063-Ab-1/ GM-Tg-bovg-SE1063-Ab-2; GM-Tg-equg-SE1063-Ab-1/ GM-Tg-equg-SE1063-Ab-2
Products NameAnti-LCN8 monoclonal antibody
Formatmab
Target NameLCN8
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-LCN8 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE1063-Ag-1Recombinant multi-species LCN8/ EP17/ LCN5 protein


    Target information

    Target IDGM-SE1063
    Target NameLCN8
    Gene ID138307,78076,366008,709395,607230,123381793,101901987,100068169
    Gene Symbol and Synonyms9230106L18Rik,EP17,ESP20.5,LCN5,LCN8,mEP17,RGD1306747
    Uniprot AccessionQ6JVE9
    Uniprot Entry NameLCN8_HUMAN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000204001
    Target ClassificationN/A

    The target: LCN8, gene name: LCN8, also named as EP17, LCN5. Members of the lipocalin family, such as LCN8, have a common structure consisting of an 8-stranded antiparallel beta-barrel that forms a cup-shaped ligand-binding pocket or calyx. Lipocalins generally bind small hydrophobic ligands and transport them to specific cells (Suzuki et al., 2004 [PubMed 15363845]).[supplied by OMIM, Aug 2009].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.